Annual Visits May Not Increase Cognitive Impairment Detection

Share this content:
Annual Visits May Not Increase Cognitive Impairment Detection
Annual Visits May Not Increase Cognitive Impairment Detection

FRIDAY, April 20, 2018 (HealthDay News) -- Medicare Annual Wellness Visits (AWVs) do not appear to substantially increase the detection of cognitive impairment in older adults, according to a study published online April 2 in the Journal of the American Geriatrics Society.

Nicole R. Fowler, Ph.D., from Indiana University in Indianapolis, and colleagues examined the effect of the Medicare AWVs on the detection of cognitive impairment and on follow-up cognitive care for older adults. The authors performed a retrospective matched-cohort study in a 5 percent random sample of fee-for-service Medicare beneficiaries enrolled continuously for 12 months before and after an index ambulatory visit from 2011 to 2013. Study participants had no claims evidence of cognitive impairment before the index visit.

The researchers found that there were no clinically relevant differences between the AWV group and matched controls in the rates of incident Alzheimer's disease and related dementia (ADRD) diagnoses (6.16 versus 6.86 percent; P < 0.001) and initiation of ADRD medications (1 versus 1.08 percent; P = 0.15), although the AWV group had higher rates testing for thyroid-stimulating hormone (39.8 versus 28.36 percent; P < 0.001), B12 (9.41 versus 6.97 percent; P < 0.001), folate (4.76 versus 3.72 percent; P < 0.001), and neurobehavioral issues (0.75 versus 0.55 percent; P < 0.001).

"Although the AWV is correlated with an increase in some measures of cognitive care, such as laboratory testing for reversible causes of cognitive impairment, it does not appear to substantially increase recognition of undetected ADRD," the authors write.

Several authors disclosed financial ties to Eli Lilly and Co., which funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »